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A peptide contained in the venom of the predatory
marine snail Conus tulipa, -TIA, has previously been
shown to possess 1-adrenoreceptor antagonist activity.
Here, we further characterize its pharmacological activ-
ity as well as its structure-activity relationships. In the
isolated rat vas deferens, -TIA inhibited 1-adrenorecep-
tor-mediated increases in cytosolic Ca2 concentration
that were triggered by norepinephrine, but did not affect
presynaptic 2-adrenoreceptor-mediated responses. In
radioligand binding assays using [125I]HEAT, -TIA dis-
played slightly greater potency at the 1B than at the 1A
or 1D subtypes. Moreover, although it did not affect the
rate of association for [3H]prazosin binding to the 1B-
adrenoreceptor, the dissociation rate was increased, in-
dicating non-competitive antagonism by -TIA. N-termi-
nally truncated analogs of -TIA were less active than
the full-length peptide, with a large decline in activity
observed upon removal of the fourth residue of -TIA
(Arg4). An alanine walk of -TIA confirmed the impor-
tance of Arg4 for activity and revealed a number of other
residues clustered around Arg4 that contribute to the
potency of -TIA. The unique allosteric antagonism of
-TIA resulting from its interaction with receptor resi-
dues that constitute a binding site that is distinct from
that of the classical competitive 1-adrenoreceptor an-
tagonists may allow the development of inhibitors that
are highly subtype selective.
1-Adrenoceptors, members of the G protein-coupled recep-
tor superfamily, are the predominant mediators of the response
to norepinephrine released from the sympathetic nerves that
innervate resistance vessels (1). Norepinephrine release mod-
ulates vascular tone and, as such, 1-adrenoreceptors are crit-
ically involved in circulatory homeostasis. Several 1-adreno-
receptor antagonists, such as the quinazoline derivative,
prazosin, are widely used for the treatment of hypertension.
1-Adrenoreceptor antagonists are also used to treat bladder
outlet obstruction in benign prostatic hyperplasia (for review,
see Ref. 2) because of their ability to relax smooth muscle.
Nevertheless, the 1-adrenoreceptor ligands developed to date
interact largely with residues of the transmembrane segments
that are homologous between the various receptor subtypes,
rather than with residues forming the framework regions (the
intra- and extracellular loops). It is not surprising, therefore,
that available agonists, and also antagonists, show limited
subtype selectivity (affinities differing by 50-fold or less be-
tween the various subtypes). For this reason, we sought to
identify novel ligands that are likely to interact allosterically
and, thus, more likely with the framework residues that are
distinct between the three 1-adrenoreceptor subtypes (1A,
1B, and 1D).
The venoms of cone snails (marine gastropods of the genus
Conus) contain bioactive peptides that disrupt neurotransmis-
sion. These compounds are referred to generically as
“conopeptides” or “conotoxins.” Individual conopeptides typi-
cally act with a high degree of specificity, yet collectively
these toxin peptides possess an extraordinarily diverse spec-
trum of pharmacological activities. This has made cone snail
venoms an attractive resource for the discovery of novel phar-
macological agents for use as therapeutics or as research
tools. Classes of conopeptides that target voltage-sensitive
Ca2 (the -conopeptides), Na (-, O-, and -conopeptides),
and K (- and A-conopeptides) channels, and nicotinic ac-
etylcholine (-, A-, and -conopeptides), 5-HT3 (-conopep-
tides), N-methyl-D-aspartic acid (conantokins), vasopressin
(conopressins), and neurotensin (contulakins) receptors have
been identified (for review, see Ref. 3). Two further classes of
conopeptides that target the norepinephrine transporter (-
conopeptides) and the 1-adrenoreceptor (	-conopeptides) have
recently been reported by us (4). The prototypical member of
the 	-conopeptide class is 	-TIA, which acts as an 1-adrenore-
ceptor antagonist. This action at the receptor contrasts with
other conopeptides presently known to target G protein-cou-
pled receptors, which act as agonists. The endogenous ligands
of these receptors are peptides, and, not surprisingly, these
conopeptides possess amino acid sequences that display high
homologies with them.
Here, we investigated the mode of action of 	-TIA, its selec-
tivity for 1-adrenoreceptor subtypes, and its structure-activity
relationships. 	-TIA is a nineteen amino acid peptide, with four
cysteine residues and an amidated C terminus. The spacing of
the cysteine residues is such that there are two intercysteine
regions (i.e. in the conformation CC----C----C), and two intramo-
lecular disulfide bonds connect the first and third and the
second and fourth cysteine residues, respectively. Structurally,
	-TIA closely resembles members of the -conopeptide class.
The similarity, however, does not extend to their pharmacolog-
ical activity. The -conopeptides act as competitive antagonists
of muscle and neuronal nicotinic ACh receptors. The most
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obvious difference between the sequences of 	-TIA and the
-conopeptides is at the N termini in the region outside of the
cysteine-bracketed loops. The majority of -conopeptides have
only a single N-terminal residue preceding the first cysteine
residue. A few other -conopeptides have been found with zero,
two, or three leading residues (5–7), but only one -conopeptide
isolated to date has four pre-cysteine N-terminal residues (8),
as found in 	-TIA. Suspecting that this region may play an
important role in conferring 1-adrenoreceptor antagonist ac-
tivity on 	-TIA, we examined the effect of the sequential re-
moval of the first four amino acid residues of 	-TIA on the
activity of the peptide. Further information on the structure-
activity relationship of 	-TIA was provided by examining the
effect of systematically substituting each non-cysteine residue
with alanine.
EXPERIMENTAL PROCEDURES
Peptide Synthesis—C-terminal amidated 	-TIA and truncated ana-
logs equivalent to residues 2–19, 3–19, 4–19, 5–19, and 1–5 of 	-TIA
were manually synthesized using t-butoxycarbonyl chemistry and
cleaved from the resin following procedures described previously (9, 10).
The amino acid sequences of the synthesized peptides are listed in
Table I. Dinitrophenyl group removal from the histidine residue was
accomplished off resin. The reduced peptides (50 mg), dissolved in a
10-ml solution of 6 M guanidine HCl, 100 mM Tris, pH 8.2, containing
diisopropylethylamine (1 ml) and 
-mercaptoethanol (2 ml), were
stirred overnight at 18 °C. The mixture was then acidified to pH 3 with
trifluoroacetic acid and purified by preparative HPLC.1 The pure re-
duced peptides were oxidized in 0.33 M NH4OAc, 0.5 M guanidine HCl,
pH 7.8, in the presence of reduced and oxidized glutathione as previ-
ously described (9). The adoption of the Cys1–Cys3, Cys2–Cys4 pattern
of disulfide connectivity by 	-TIA and the truncated analogs was veri-
fied by NMR techniques. Analogs of 	-TIA in which single residues were
replaced with alanine were synthesized using Fmoc chemistry. The
chain assembly of the peptides was performed on a manual shaker
system using HBTU activation protocols (10) to couple the Fmoc-pro-
tected amino acid to the resin. The Fmoc protecting group was removed
using 50% piperidine in dimethylformamide, and dimethylformamide
was used as both the coupling solvent and for flow washes throughout
the cycle. The progress of the assembly was monitored by quantitative
ninhydrin monitoring (11). Peptide was deprotected and cleaved from
the resin by stirring at room temperature in trifluoroacetic acid/H2O/
triisopropyl silane/EDT (90:5:2.5:2.5) for 2–3 h. Cold diethyl ether was
then added to the mixture and the peptide precipitated out. The pre-
cipitate was collected by centrifugation and subsequently washed with
further cold diethyl ether to remove scavengers. The final product was
dissolved in 50% aqueous acetonitrile and lyophilized to yield a fluffy
white solid. The crude, reduced peptide was examined by reverse phase
HPLC for purity, and the correct molecular weight confirmed by elec-
trospray mass spectrometry. Pure, reduced peptides were oxidized, and
the major peak was purified to95% purity and characterized by HPLC
prior to further use.
Isolated Rat Vas Deferens—Vasa deferentia were excised from male
Wistar rats (250–350 g) killed by a blow to the head, and exsangui-
nated. Epididymal and prostatic portions were bisected transversely
and mounted in 5 ml organ baths under a resting tension of 0.5 g in
physiological salt solution containing (mM): NaCl, 119; KCl, 4.7; MgSO4,
1.17; KH2PO4, 1.18; NaHCO3, 25.0; D-()-glucose, 5.5; CaCl2, 2.5;
EDTA, 0.026; maintained at 37 °C, and bubbled with 5% CO2/95% O2.
Longitudinal tension was measured using isometric force transducers
and recorded digitally (MacLab/8s data acquisition system; ADInstru-
ments, Sydney, Australia). In the first set of experiments, a cumulative
concentration-response curve for the contraction of the epididymal vas
deferens elicited by exogenously applied norepinephrine was estab-
lished. The preparations were then washed several times with drug-free
solution. After 15 min, a dose of 	-TIA was added to the organ bath and
equilibrated with the tissues for 20 min before a second concentration-
response curve to norepinephrine was generated. In other experiments,
	-TIA was assayed for 2-adrenoreceptor antagonist activity. Prostatic
tissue segments were field stimulated with a single electrical pulse of 55
V amplitude and 1 ms duration generated by a Grass S44 stimulator
(Grass Instruments, Quincy, MA) at 20 s intervals. Prazosin was added
to the baths to a final concentration of 0.5 M to block 1-adrenorecep-
tors, and equilibrated with the tissues for 20 min before doses of
norepinephrine were added in half-log unit steps to establish cumula-
tive concentration-response curves. Each dose of norepinephrine was
added after the effect of the previous dose had reached its maximum.
The tissues were then washed with drug-free solution several times and
allowed to recover for 30 min. At this time, the prazosin (0.5 M) was
replaced and 10 M 	-TIA was added. After 20 min, a second concen-
tration-response curve to norepinephrine was generated. In the final set
of experiments, the N-terminal truncated analogs of 	-TIA listed in
Table I were assayed for 1-adrenoreceptor antagonist activity. The
bisected prostatic vas deferens segments were stimulated as before, but
at 3 min intervals. 	-TIA or one of its truncated analogs was added to
the organ bath to a final concentration of 10 M, and the peptide’s effect
on the tissue’s contractile response was assessed.
Isolation of Smooth Muscle Cells—Vasa deferentia were excised from
10–14-day-old and  6-week-old Wistar rats killed by exposure to
halothane. Adventitia and blood vessels were removed using a pair of
fine forceps. The vasa deferentia were halved and incubated at room
temperature in fresh Ca2- and Mg2-free Hanks balanced salt solution
(HBSS) for 5 min. Portions of vas deferens were placed in 2 ml Ca2-free
HBSS containing 2 mg/ml collagenase (type B, Roche Applied Science)
and bubbled with 95% O2, 5% CO2 for 1 h at 30 °C. The tissue pieces
were then cut into smaller fragments and further incubated in fresh
enzyme-containing solution in three 10 min stages. The vas deferens
fragments were slightly agitated to enhance cellular dissociation. At the
end of each stage, cells in the supernatant were collected and placed in
fresh solution. Bovine serum albumin (1 mg/ml) was added, and the cell
suspension was kept at 4 °C for 2 h. Cells were then plated on 25 mm
round glass cover-slips in Petri dishes containing Dulbecco’s modified
Eagle’s medium and used within 48–72 h.
Fura-2 Fluorometric Measurements—Cover-slips holding cells were
mounted in a recording chamber and constantly perfused with bath
solution containing (mM): NaCl, 150; KCl, 5.4; HEPES, 10; D-glucose,
10; CaCl2, 1; MgCl2, 1; pH 7.4, at a rate of 2 ml/min. The loading
procedure was similar to that described by Liu et al. (12). Briefly, cells
were incubated for 1 h in bath solution containing 5 M Fura-2, AM, and
0.02% Pluronic-127 detergent. After loading, the cells were incubated
for a further 30 min in fresh bathing solution to allow de-esterification.
Fluorescent signals were acquired using a Photon Technology Interna-
tional photomultiplier detection system driven by the Felix software
package, and free Ca2 concentrations were calculated from the ratio of
emissions at 510 nm following excitement with wavelengths of 340 nm
and 380 nm as described by Grynkiewicz et al. (13). Fluorescent re-
sponses elicited by the application of norepinephrine or ATP (both 10
M) in the absence and presence of 	-TIA were monitored. The experi-
ments were carried out at room temperature (23 °C).
Membrane Preparation and DNA Constructs—COS-1 cells (ATCC;
Manassas, VA) were cultured in Dulbecco’s modified Eagle’s medium
containing penicillin, streptomycin, glutamine, and 5% fetal bovine
serum. At 60–80% confluency, the cells were transiently transfected
with plasmid DNA incorporating 1-adrenoreceptor cDNA in the mod-
ified eukaryotic expression vector pMT2 using the DEAE-dextran
method (14), as previously described (15). In some experiments, COS-7
cells (ECACC; Salisbury, Wiltshire, UK) were used. These were cul-
tured in Dulbecco’s modified Eagle’s medium containing 10% fetal bo-
vine serum and transiently transfected with the 1-adrenoreceptor
using LipofectAMINE 2000 reagent (Invitrogen) following the manu-
facturer’s protocol. Three different plasmid constructs were used: one
for the rat 1A-adrenoreceptor subtype (16), one for the hamster 1B-
adrenoreceptor (17), and another for the rat 1D-adrenoreceptor (18).
Membranes were prepared 24 h post-transfection as described previ-
ously (18), and resuspended in HEM buffer (20 mM HEPES, 1.5 mM
EGTA, 12.5 mM MgCl2, pH 7.5) containing 10% v/v glycerol and stored
at 80 °C. The protein concentration of the prepared membranes was
determined by the method of Bradford (19).
Radioligand Binding Assays—To determine the 1-adrenoreceptor
subtype selectivity of 	-TIA, the effect of 	-TIA on the binding of the
radiolabelled 1-adrenoreceptor antagonist [
125I]HEAT was examined.
Reactions containing [125I]HEAT (70 pM), membranes from 1-adreno-
receptor-transfected COS-1 cells (1 g protein), HEM buffer, and in-
creasing concentrations of 	-TIA were set up in polypropylene tubes and
incubated at room temperature for 60 min. The assays were performed
in duplicate in a total reaction volume of 250 l. Nonspecific binding
1 The abbreviations used are: HPLC, high-performance liquid chro-
matography; NMR, nuclear magnetic resonance; HBTU, N,N,N,N-
tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate);
EDT, ethanedithiol; [125I]HEAT, [125I]-2-[
-(3-iodo-4-hydroxyphenyl)-
ethylaminomethyl tetralone; Fmoc, N-(9-fluorenyl)methoxycarbonyl;
GABAA, -aminobutyric acid, Type A.
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was determined in the presence of 100 M phentolamine. Reactions
were stopped by the addition of ice-cold HEM buffer, and the tubes’
contents were filtered under vacuum onto Whatman GF/C glass filters
with a Brandel cell harvester. The filters were washed 5 times with
ice-cold HEM buffer, and the amount of filter-bound radioactivity was
determined using a Packard Auto- 500 counter.
In other binding experiments, [3H]prazosin was used as the radioli-
gand. To examine the effect of 	-TIA on the rate of association of
[3H]prazosin to the 1B-adrenoreceptor, reactions containing [
3H]prazo-
sin (0.25 nM), membranes from COS-7 cells transiently transfected with
the 1B-adrenoreceptor (2.5 g protein), HEM buffer were set up in
duplicate in the absence and presence of 	-TIA (17.5 nM). The amount of
nonspecific binding was determined as described above. Binding was
allowed to proceed for 0–90 min. The effect of 	-TIA on the rate of
dissociation of [3H] prazosin from the 1B-adrenoreceptor was investi-
gated in assays where phentolamine (100 M) with and without 	-TIA
(10 M) was added to reactions containing [3H]prazosin (0.43 nM) and
1B-adrenoreceptor membranes (7 g protein) that had previously been
incubated for 60 min. In experiments with alanine-substituted analogs
of 	-TIA, [3H]prazosin (0.43 nM) and 1B-adrenoreceptor membranes (7
g protein) were incubated for 60 min with increasing concentrations of
peptide (1011105 M). The reaction volume was 150 l. Membranes
were harvested onto Whatman GF/B filtermats using a Tomtec har-
vester. BetaPlate scintillant (PerkinElmer Life Sciences) was applied
and the filter-bound radioactivity detected using a Wallac MicroBeta
counter.
Statistics and Data Analysis—Curves were fitted to the individual
data points of sets of 3–6 separate experiments by non-linear regression
using Prism 3 software for Macintosh (GraphPad Software, San Diego,
CA). Results are expressed as means S.E. Student’s t test was used to
compare the curve-fitting parameters between treatments, and analy-
sis of variance with post hoc t tests performed by the Tukey method was
used for multiple comparisons. Values of p  0.05 were considered
significant.
Materials—Adenosine 5-triphosphate disodium salt, ()-norepi-
nephrine bitartrate salt, phentolamine hydrochloride, and prazosin hy-
drochloride were obtained from Sigma. Collagenase type B and 1,4-
dithiothreitol were obtained from Roche Applied Science. Fura-2, AM,
and Pluronic-127 were obtained from Molecular Probes (Eugene,
Oregon). [125I]HEAT (specific activity, 2200 Ci/mmol) and [7-methoxy-
3H]prazosin (specific activity, 87 Ci/mmol) were from PerkinElmer Life
Sciences. Protected Fmoc-amino acid derivatives were from Novabio-
chem or Auspep (Melbourne, Australia). Dimethylformamide, dichlo-
romethane, diisopropylethylamine, and trifluoroacetic acid were all
peptide synthesis grade supplied by Auspep. HBTU was Fluka no.
12804 supplied by Sigma. HPLC grade acetonitrile and methanol was
supplied by Sigma. Resin used was Fmoc-rink amide resin supplied by
Polymer Labs. Triisopropyl silane was from Aldrich Chemicals.
RESULTS
1-Adrenoreceptor Antagonism—The application of norepi-
nephrine (1 M) to dissociated smooth muscle cells from the
vasa deferentia of adult rats elicited an increase in the intra-
cellular free Ca2 concentration ([Ca2]i) from 19  3.3 nM to
130  26 nM (n  9). In cells from juvenile rats, the same
concentration of norepinephrine raised the Ca2 concentration
from 32  7.6 nM to 309  46 nM (n  4). The magnitude of the
elicited responses, but not the resting Ca2 levels, were signif-
icantly different between adult and juvenile rats. In both age
groups, the responses could be abolished by prazosin (10 nM),
indicating that they were mediated by 1-adrenoreceptors.
	-TIA inhibited the Ca2 responses of adult cells with an IC50
of 133 nM (pIC50  6.88  0.05) and juvenile cells with an IC50
of 470 nM (pIC50  6.33  0.03) (Fig. 1). Neither curve’s bottom
was significantly different from zero, indicating that 	-TIA acts
as a full inhibitor. The juvenile concentration-response curve
was significantly steeper than the adult curve, with a Hill slope
parameter of 2.6  0.4 compared with 0.89  0.10. 	-TIA (1
M) had no effect on the Ca2 response of the isolated smooth
muscle cells that was evoked by 10 M ATP (n  3; data not
shown).
1-Adrenoreceptor But Not 2-Adrenoreceptor Antagonism—
The effect of various concentrations of 	-TIA on the 1-adreno-
receptor-mediated contractile responses of isolated segments of
rat vas deferens to exogenously applied norepinephrine is
shown in Fig. 2A. In the absence of 	-TIA, the EC50 of norepi-
nephrine was determined to be 9.3 M (pEC50  5.0  0.03).
This value was increased to 32 M (pEC50  4.5  0.07), 51 M
(pEC50 4.3 0.09), and to 166 M (pEC50 3.3 0.08) in the
presence of 1, 3, and 10 M 	-TIA, respectively. The maximum
response of the tissue to norepinephrine was 99  4.4% of the
control response when 1 M 	-TIA was present and 82  4.9%
and 42  3.4% in the presence of 3 and 10 M 	-TIA, re-
spectively. The decline in the maximum response following
treatment with the two highest concentrations of 	-TIA was
significant (p  0.001).
The bisected rat prostatic vas deferens responded to electri-
cal field stimulation with a biphasic contraction, reflecting the
distinct time courses for the postsynaptic actions of the sym-
pathetic co-transmitters ATP and norepinephrine in the tissue
(20). Following the addition of prazosin, the previously biphasic
response consisted of only the first component. This prazosin-
resistant component could be abolished by activating 2-adre-
noreceptors with exogenously applied norepinephrine. The IC50
for the inhibition by norepinephrine was 1.1 M (pIC50  6.0 
0.10) (Fig. 2B). In the presence of 	-TIA (10 M), the IC50 was
not significantly different (pIC50  5.9  0.13). Neither nore-
pinephrine nor 	-TIA had a direct effect on the resting tension
of the preparation.
1-Adrenoreceptor Subtype Selectivity and Effect on [
3H]pra-
zosin Binding Kinetics—	-TIA inhibited the binding of
[125I]HEAT to all three cloned 1-adrenoreceptor subtypes (Fig.
3). The IC50 values for 	-TIA were 150 nM (pIC50  6.8  0.04)
at the 1A-adrenoreceptor; 70 nM (pIC50  7.15  0.06) at the
1B-adrenoreceptor; and 340 nM (pIC50  6.5  0.05) at the
FIG. 1. Effect of -TIA on the norepinephrine-evoked Ca2 re-
sponse of isolated rat vas deferens smooth muscle cells. A, the
increase in cytosolic Ca2 concentration of an isolated adult rat vas
deferens smooth muscle cell elicited by the application of norepineph-
rine (10 M; indicated by arrows) was attenuated in the presence of
	-TIA. B, concentration-response curves for the inhibition of the Ca2
response by 	-TIA in adult (E) and juvenile (f) rat cells were con-
structed. Symbols represent the mean  S.E. of data from six
experiments.
1-Adrenoreceptor Antagonism by 	-TIA 34453
 by on Septem
ber 4, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
1D-adrenoreceptor. The difference in the potency of 	-TIA
between 1-adrenoreceptor subtypes was significant for all sets
of comparisons (p  0.001). The Hill slope parameters for the
effect of 	-TIA were not significantly different from unity.
The effect of 	-TIA on the association rate of [3H]prazosin
binding to 1B-adrenoreceptors is shown in Fig. 4A. In the
absence of 	-TIA, the observed rate constant for the association
of [3H]prazosin (kob) was determined to be 0.101  0.008
min1. The kob in experiments with 	-TIA present was 0.119 
0.013 min1, which is not significantly different from the con-
trol value. The total specific binding was reduced from 2.50 
0.052 pmol/mg protein to 1.52  0.041 pmol/mg protein in the
presence of 	-TIA (17.5 nM). The difference in the amount of
total specific binding achieved in the absence and presence of
	-TIA was highly significant (p  0.001).
The dissociation of [3H]prazosin from the 1B-adrenorecep-
tors (Fig. 4B) proceeded at a rate of 0.50  0.03 h1 in control
experiments. In the presence of 	-TIA (10 M), the dissociation
rate constant (koff) was increased significantly to 1.15  0.06
h1 (p  0.001).
Truncated Analogs of 	-TIA—All of the N-terminal truncated
analogs of 	-TIA (see Table I) tested were active in the vas
deferens assay, causing selective inhibition of the second com-
ponent of the biphasic contraction as observed for 	-TIA. How-
ever, the N-terminal tail alone, TIA1–5, had no effect on either
phase of the contraction at a concentration of 10 M. The
deletion of N-terminal residues from 	-TIA was associated with
a loss in activity, demonstrated by the relative extent of the
second component that remained after treatment with the an-
alogs and full-length 	-TIA (all 10 M; Fig. 5).
Alanine Walk of 	-TIA—The potencies of 	-TIA and its ala-
nine-substituted analogs at the 1B-adrenoreceptor are com-
pared in Fig. 6. All of the peptides acted as full inhibitors of
specific [3H]prazosin binding and none of the Hill slope param-
eters of the concentration-response curves were significantly
different from unity. The potency of 	-TIA was the same
whether the binding reaction was allowed to proceed for 60 or
120 min (data not shown). Of the fourteen analogs tested, six
were found to be significantly less potent than 	-TIA. The
greatest loss of potency was seen upon replacement of the
arginine residue at position 4, which resulted in a reduction in
potency of 270-fold compared with the native conopeptide.
DISCUSSION
As a peptide, 	-TIA is structurally unique among the 1-
adrenoreceptor antagonists described to date, some of which
were also originally isolated from natural sources (e.g. the
plant alkaloids corynanthine, dicentrine, and dehydroevodia-
mine). We have explored the pharmacology of 	-TIA in func-
tional and binding assays, and found that the uniqueness of
	-TIA compared with other 1-adrenoreceptor antagonists also
extends to its mechanism of action.
Functional 1-adrenoreceptor antagonism by 	-TIA was
demonstrated at both the tissue and cellular level through its
ability to inhibit the norepinephrine-evoked increases in cyto-
solic free Ca2 concentration and contractility. The vast major-
ity of known 1-adrenoreceptor antagonists act competitively
with respect to norepinephrine. 	-TIA, however, behaves as a
non-competitive antagonist. This was indicated in these exper-
iments by the effect of the peptide to inhibit the maximum level
FIG. 2. Effect of -TIA in functional assays for 1- and 2-adre-
noreceptor antagonism. A, concentration-response curves for the
contractile response elicited by the activation of 1-adrenoreceptors by
exogenously applied norepinephrine measured in the absence (E) and
presence of 	-TIA (, 1 M; Œ, 3 M; f, 10 M). B, concentration-
response curves for the inhibition of the electrically evoked response of
the rat vas deferens due to the activation of presynaptic 2-adrenore-
ceptors by exogenously applied norepinephrine measured in the ab-
sence (E) and presence (f) of 10 M 	-TIA. Symbols represent the
mean  S.E. of data from five experiments.
FIG. 3. Effect of -TIA at 1-adrenoreceptor subtypes. Concen-
tration-response curves for inhibition by 	-TIA of the specific binding of
the 1-adrenoreceptor antagonist [
125I]HEAT to membranes from
COS-1 cells transiently transfected with the rat 1A- (f), hamster 1B-
(), or rat 1D-adrenoreceptor (Œ). Symbols represent the mean  S.E.
of data from three separate experiments performed in duplicate.
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of the 1-adrenoreceptor-mediated contractile response proving
to be incapable of being surmounted by increasing the concen-
tration of applied norepinephrine.
Changes in various aspects of 1-adrenergic neurotransmis-
sion associated with age have been reported (21–23), so poten-
tial age-related differences in the inhibitory action of 	-TIA
were examined. This was investigated in dissociated cells only,
because the contractile response of the juvenile rat vas defer-
ens is quite weak (24). 	-TIA was 3.5 times more potent at
inhibiting Ca2 spikes following 1-adrenoreceptor activation
by norepinephrine in cells from adult rats compared with those
taken from juvenile rats. This might be due to an altered
pattern of expression of 1-adrenoreceptor subtypes with age,
as has been reported to occur in other tissues (25). Each of the
three cloned 1-adrenoreceptor subtypes play a functional role
in the adult rat vas deferens (26–29), with the 1A subtype
generally agreed to be the principal mediator of responses to
norepinephrine. The difference in potency of 	-TIA in juvenile
and adult rats is similar in magnitude to the range in potency
across the three cloned 1-adrenoreceptors that was observed
in the binding experiments. Involvement of the putative pra-
zosin-insensitive 1L-adrenoreceptor described by Ohmura et
al. (30) in influencing 	-TIA potency, can, however, be ruled
out as both adult and juvenile Ca2 responses were fully
inhibited by a low dose of prazosin. Also, because the assays
were performed using isolated smooth muscle cells, we can
exclude the impact of changes in the effectiveness of the
neuronal norepinephrine reuptake system that occur with
age (31) as a reason for the disparate potency of 	-TIA in
juvenile and adult rats.
As well as the difference in potency, a change in the Hill
slope of the concentration-response curve for 	-TIA was seen
between rats from the two age groups, with the data from
FIG. 4. Effect of -TIA on the kinetics of [3H]prazosin binding.
A, association of [3H]prazosin to 1B-adrenoreceptors over time in the
absence (E) and presence (f) of 17.5 nM 	-TIA. B, dissociation of
[3H]prazosin from 1B-adrenoreceptors over time in the absence (E) and
presence (f) of 10 M 	-TIA. Symbols represent the mean S.E. of data
obtained from three separate experiments. Some error bars are ob-
scured by the symbols.
TABLE I
Amino acid sequence of 	-TIA and N-terminal truncated analogs
Descriptions of connectivity refer to the presence of disulfide bonds
between cysteine residues (in bold) numbered sequentially with respect
to the linear sequence. * indicates an amidated C terminus.
Peptide Amino acid sequence Connectivity
	-TIA FNWRCCLIPACRRNHKKFC* 1–3, 2–4
TIA2–19 NWRCCLIPACRRNHKKFC* 1–3, 2–4
TIA3–19 WRCCLIPACRRNHKKFC* 1–3, 2–4
TIA4–19 RCCLIPACRRNHKKFC* 1–3, 2–4
TIA5–19 CCLIPACRRNHKKFC* 1–3, 2–4
TIA1–5 FNWRC* none
FIG. 5. 1-Adrenoreceptor antagonist activity of -TIA and its
N-terminal truncated analogs. Comparison of the effect of 	-TIA and
the five truncated analogs (all 10 M) on the magnitude of the nora-
drenergic component of the response of the rat vas deferens to electrical
field stimulation. Bars represent the mean  S.E. of results obtained
from 3–5 experiments.
FIG. 6. Comparison of the potencies of -TIA and its alanine-
substituted analogs for the 1-adrenoreceptor. A series of analogs
of 	-TIA in which its non-cysteine residues were systematically replaced
with alanine were assayed for inhibition of [3H]prazosin binding to the
membranes of COS-7 cells transfected with the hamster 1B-adrenore-
ceptor. Bars represent the mean  S.E. of the analogs’ pIC50 values
determined from three concentration-response curves, with each con-
centration point on a single curve tested in triplicate. * indicates p 
0.05 and ** indicates p  0.001 compared with 	-TIA.
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younger animals exhibiting a much steeper inhibition profile.
The relationship between 1-adrenoreceptor activation and
functional response is known to be non-linear in the adult rat
vas deferens (32, 33), giving rise to the phenomenon of “spare
receptors,” and the efficiency of receptor-effector coupling is
recognized to vary between 1-adrenoreceptor subtypes (34).
Tighter receptor-effector coupling in the rat vas deferens of
juvenile animals, with or without a change in the identity of the
adrenoreceptor subtypes mediating the response, would act to
reduce the apparent potency of a non-competitive inhibitor like
	-TIA by requiring that a greater proportion of the receptor
pool be inactivated to achieve the same level of inhibition.
Furthermore, the concentration-response curve for inhibition
would steepen as the relationship between receptor activation
and response became more strongly hyperbolic. Our observa-
tion that the norepinephrine-evoked Ca2 responses of cells
from juvenile animals were substantially larger than those of
older animals may indicate a decline in 1-adrenoreceptor sig-
naling efficiency with age. The presence of spare receptors in
the adult rat vas deferens explains why 	-TIA initially shifted
the concentration-response curve for norepinephrine to the
right without an accompanying decline in the maximum re-
sponse, as was evident in the presence of the two higher con-
centrations of 	-TIA.
In light of 	-TIA’s modest 1-adrenoreceptor subtype selec-
tivity, it was of interest to investigate whether 2-adrenorecep-
tors were a target of 	-TIA. The finding that 	-TIA (10 M) did
not protect the evoked responses from inhibition by norepi-
nephrine, as 2-adrenoreceptor antagonists such as yohimbine
have been demonstrated to do in this assay (35), indicates that
the peptide does not block 2-adrenoreceptors.
To investigate the mode of action of 	-TIA at the 1-adreno-
receptor, the effect of 	-TIA on the kinetics of [3H]prazosin
binding to the receptor was examined. The 1B subtype was
used as the prototypical 1-adrenoreceptor in these experi-
ments because it is at this subtype that 	-TIA displays the
highest potency. Confirming that 	-TIA does not block the
1-adrenoreceptor through a competitive interaction, the rate
constant observed for the association of [3H]prazosin to 1B-
adrenoreceptors was unchanged in the presence of 	-TIA and
not reduced as would have been expected if the conopeptide
acted competitively. The decline in the amount of equilibrium
binding without a change in the rate constant for association
when 	-TIA was included in the binding reaction is consistent
with the conopeptide disrupting [3H]prazosin binding through
an allosteric interaction. We suggest then that the agonist
binding site, which is recognized by norepinephrine and com-
petitive antagonists such as HEAT and prazosin, and the 	-TIA
site on the 1-adrenoreceptor are distinct. Upon binding of
	-TIA to its site on the 1-adrenoreceptor, the receptor loses its
ability to recognize agonists and competitive antagonists
through an allosteric action of 	-TIA to disrupt the structure of
the agonist-binding site, reducing the size of the pool of avail-
able receptors for these ligands.
The increase in the rate of dissociation of [3H]prazosin from
the 1-adrenoreceptor in the presence of 	-TIA reveals that the
conopeptide can still bind to the receptor when [3H]prazosin is
already bound and that 	-TIA promotes the dissociation of
[3H]prazosin from the receptor. The R	-TIAprazosin complex
can not be distinguished from the Rprazosin complex in these
experiments because both species are radiolabelled. Conse-
quently, the rate of dissociation observed in the presence of
	-TIA reflects a combination of the rates of [3H]prazosin disso-
ciation from both the Rprazosin and the R	-TIAprazosin com-
plexes. The relative contribution of each dissociation reaction
to the overall rate that is measured depends on the two rate
constants and also the relative concentrations of Rprazosin
and R	-TIAprazosin. The modest increase in the observed rate
(2.3 times faster) in the presence of a high concentration of
	-TIA, which fully inhibits specific [3H]prazosin equilibrium
binding (10 M), might indicate that the affinity of 	-TIA for the
1-adrenoreceptor is lower when [
3H]prazosin is bound than it
is for the unoccupied receptor. Such a situation would repre-
sent bidirectional negative allosteric modulation between the
competitive antagonist and 	-TIA binding sites.
In addition to the 	-conopeptides, two other classes of allos-
teric modulators of the 1-adrenoreceptor have been reported,
but neither act in the same manner as 	-TIA. The allosteric
effect of the benzodiazepines diazepam, lorazepam, and mida-
zolam at the 1-adrenoreceptor was reported by Waugh et al.
(36). These agents are better known for their allosteric effect at
the GABAA receptor, where they do not activate the receptor
themselves, but act to increase the affinity and efficacy of the
endogenous agonist GABA (37, 38). Like 	-TIA, these three
benzodiazepines were found to inhibit [125I]HEAT binding, al-
though much less potently, with IC50 values at the human
1-adrenoreceptor subtypes of 100 M (36). Unlike 	-TIA,
however, the benzodiazepines were found to act as weak partial
agonists of 1-adrenoreceptors by themselves in functional as-
says, and to increase the maximum response and EC50 of both
full and partial 1-adrenoreceptor agonists. This indicates a
dual allosteric effect of the benzodiazepines to simultaneously
reduced the affinity of the agonist-binding site for ligand and to
increase the affinity of the agonist-bound form of the receptor
for G-protein, effects not observed with 	-TIA. The other class
of 1-adrenoreceptor allosteric modulators are the amiloride
analogs. Leppik et al. (39) found that amiloride and its analogs
increased the rate of dissociation of [3H] prazosin from the
1-adrenoreceptor, as 	-TIA does here. However, the amiloride
analogs were found not to inhibit the saturability of radioligand
binding as has been shown to occur with 	-TIA (4). This implies
that the allosteric effect of the amiloride analogs on the struc-
ture of the competitive antagonist-binding site is more subtle
than that of 	-TIA, with the conopeptide seemingly abolishing
the binding site rather than merely changing its structure so
that the receptor can still recognize the ligands only with less
affinity.
Our attempts to gain an insight into the structural basis
for 	-TIA’s 1-adrenoreceptor antagonist activity initially fo-
cused on the N-terminal region of the peptide. This section
FIG. 7. Location of amino acid residues of -TIA important for
1-adrenoreceptor antagonist activity. The best of twenty struc-
tures of 	-TIA determined by NMR (1) was used to generate a model of
the three-dimensional surface of the peptide within INSIGHT II (Ac-
celrys, San Diego, CA). Protein Data Bank accession number for co-
ordinates, 1IEN. The models shown in A and B are rotated 90° around
the y-axis. Positively charged residues are colored blue, hydrophobic
residues yellow, and uncharged polar residues gray. The cluster of
residues whose replacement with alanine caused a significant change in
the potency of the peptide at the 1-adrenoreceptor are labeled.
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was chosen for study because it displays the least homology
to the -conopeptides, a class whose members are, structur-
ally, otherwise quite similar to 	-TIA but do not block 1-
adrenoreceptors. We found that the N-terminal region of
	-TIA alone is not sufficient for 1-adrenoreceptor antagonist
activity, demonstrated by the lack of activity of the TIA1–5
analog. The sequential removal of the first three residues of
	-TIA had a small detrimental effect on activity, but it was
upon the removal of the fourth residue of full-length 	-TIA (in
the form of the analog TIA5–19) that the largest impact on
activity was seen. Assuming that TIA5–19 acts with a Hill
slope of unity, the observation that 65% of the response
remains after treatment with the analog at a concentration of
10 M implies that TIA5–19 is 34-fold less potent than full-
length 	-TIA. Thus, a substantial role for the residue located
in position 4 of 	-TIA in conferring 1-adrenoreceptor activity
on 	-TIA is indicated. This was also the conclusion to be
drawn from the results of the alanine walk of 	-TIA, where
the substitution of Arg4 with alanine had the largest impact
on 1-adrenoreceptor antagonist potency of all the replace-
ments made. Residue replacement has little effect on the
robust structures of the -conopeptides,2 so it would be ex-
pected that 	-TIA will behave similarly given the structural
similarity between the two conopeptide classes. The three-
dimensional structure of 	-TIA (Fig. 7) shows that the Arg4
sidechain is exposed and surrounded by a cluster of other
residues also identified in the alanine walk to contribute to
	-TIA’s 1-adrenoreceptor antagonist activity. The impor-
tance of Arg4 could reflect an interaction of the positive
charge of this side chain with a complementary negatively
charged residue on the 1-adrenoreceptor. The small degree
of subtype selectivity possessed by 	-TIA implies that its
binding site is conserved across 1-adrenoreceptors, and
given the size and chemical nature of 	-TIA, we would expect
that this site is located on an extracellularly exposed portion
of the receptor. The 1A-, 1B-, and 1D-adrenoreceptor sub-
types display 32% sequence identity in their predicted extra-
cellular domains (40), with several conserved negatively
charged residues present.
In summary, the venom peptide 	-TIA acts as a reversible,
non-competitive 1-adrenoreceptor antagonist with some sub-
type selectivity. The discovery of a peptide ligand that disrupts
1-adrenoreceptor operation raises the possibility that endog-
enous peptides or proteins that act in the same manner might
exist. The endogenous circulating factor implicated by Shapiro
et al. (41) in the pathogenesis of sympathotonic orthostatic
hypotension may be such a compound. In addition, the eluci-
dation and characterization of a peptide that allosterically in-
hibits 1-adrenoreceptors by interacting with residues distinct
from those of the poorly selective classical inhibitors suggests
that the development of highly subtype-selective compounds
should be feasible. Such agents are likely to have major ther-
apeutic advantages over the existing ligands.
Acknowledgments—We thank Trudy Milne, Sebastien Dutertre, and
John Gehrmann (Institute for Molecular Bioscience, The University of
Queensland) for their assistance.
REFERENCES
1. Langer, S. Z., and Shepperson, N. B. (1982) J. Cardiovasc. Pharmacol. 4,
S8-S13
2. Tammela, T. (1997) Drugs Aging 10, 349–366
3. Olivera, B. M., and Cruz, L. J. (2001) Toxicon 39, 7–14
4. Sharpe, I. A., Gehrmann, J., Loughnan, M. L., Thomas, L., Adams, D. A.,
Atkins, A., Palant, E., Craik, D. J., Adams, D. J., Alewood, P. F., and Lewis,
R. J. (2001) Nature Neurosci. 4, 902–907
5. Martinez, J. S., Olivera, B. M., Gray, W. R., Craig, A. G., Groebe, D. R.,
Abramson, S. N., and McIntosh, J. M. (1995) Biochemistry 34, 14519–14526
6. Favreau, P., Krimm, Y., Le Gall, F., Bobenrieth, M. J., Lamthanh, H., Bouet,
F., Servent, D., Molgo, J., Me´nez, A., Letourneux, Y., and Lancelin, J. M.
(1999) Biochemistry 38, 6317–6326
7. McIntosh, J. M., Cruz, L. J., Hunkapiller, M. W., Gray, W. R., and Olivera,
B. M. (1982) Arch. Biochem. Biophys. 218, 329–334
8. Nicke, A., Loughnan, M. L., Millard, E. L., Alewood, P. F., Adams, D. J., Daly,
N. L., Craik, D. J., and Lewis, R. J. (2002) J. Biol. Chem. 278, 3137–3144
9. Nielsen, K. J., Adams, D., Thomas, L., Bond, T., Alewood, P. F., Craik, D. J.,
and Lewis, R. J. (1999) J. Mol. Biol. 289, 1405–1421
10. Schnolzer, M., Alewood, P., Jones, A., Alewood, D., and Kent, S. B. (1992) Int.
J. Pept. Protein Res. 40, 180–193
11. Sarin, V. K., Kent, S. B., Tam, J. P., and Merrifield, R. B. (1981) Anal. Biochem.
117, 147–157
12. Liu, D. M., Katnik, C., Stafford, M., and Adams, D. J. (2000) J. Physiol. 526,
287–298
13. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) J. Biol. Chem. 260,
3440–3450
14. Cullen, B. R. (1987) Methods Enzymol. 152, 684–704
15. Chen, S., Lin, F., Xu, M., Hwa, J., and Graham, R. M. (2000) EMBO J. 19,
4265–4271
16. Perez, D. M., Piascik, M. T., Malik, N., Gaivin, R., and Graham, R. M. (1994)
Mol. Pharmacol. 46, 823–831
17. Hwa, J., Graham, R. M., and Perez, D. M. (1995) J. Biol. Chem. 270,
23189–23195
18. Perez, D. M., Piascik, M. T., and Graham, R. M. (1991) Mol. Pharmacol. 40,
876–883
19. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254
20. Sneddon, P., and Westfall, D. P. (1984) J. Physiol. (Lond.) 347, 561–580
21. MacDonald, A., and McGrath, J. C. (1984) Br. J. Pharmacol. 82, 25–34
22. Takayanagi, I., Shinkai, M., and Yamasawa, K. (1989) Can. J. Physiol. Phar-
macol. 67, 1398–1402
23. Markus, R. P., and de Avellar, M. C. (1997) J. Auton. Pharmacol. 17, 147–154
24. Chiu-Wei, Y. F., Kasuya, Y., and Watanabe, M. (1984) Q. J. Exp. Physiol. 69,
703–710
25. Shen, H., Peri, K. G., Deng, X. F., Chemtob, S., and Varma, D. R. (2000) Can.
J. Physiol. Pharmacol. 78, 237–243
26. Aboud, R., Shafii, M., and Docherty, J. R. (1993) Br. J. Pharmacol. 109, 80–87
27. Burt, R. P., Chapple, C. R., and Marshall, I. (1998) Br. J. Pharmacol. 123,
317–325
28. Honner, V., and Docherty, J. R. (1999) Br. J. Pharmacol. 128, 1323–1331
29. Mallard, N. J., Marshall, R. W., Sithers, A. J., and Spriggs, T. L. B. (1992)
Br. J. Pharmacol. 105, 727–731
30. Ohmura, T., Oshita, M., Kigoshi, S., and Muramatsu, I. (1992) Br. J. Phar-
macol. 107, 697–704
31. de Avellar, M. C., Kobashi, Y. L., and Markus, R. P. (1990) Naunyn-Schmiede-
berg’s Arch. Pharmacol. 341, 295–300
32. Diaz-Toledo, A., and Marti, M. C. (1988) Eur. J. Pharmacol. 156, 315–324
33. Minneman, K. P., and Abel, P. W. (1984) Mol. Pharmacol. 25, 56–63
34. Theroux, T. L., Esbenshade, T. A., Peavy, R. D., and Minneman, K. P. (1996)
Mol. Pharmacol. 50, 1376–1387
35. Leedham, J. A., and Pennefather, J. N. (1982) Br. J. Pharmacol. 77, 293–299
36. Waugh, D. J., Gaivin, R. J., Damron, D. S., Murray, P. A., and Perez, D. M.
(1999) J. Pharmacol. Exp. Ther. 291, 1164–1171
37. Costa, E., Guidotti, A., and Mao, C. C. (1975) Adv. Biochem. Psychopharmacol.
14, 113–130
38. Haefely, W., Kulcsar, A., Mohler, H., Pieri, L., Polc, P., and Schaffner, R. (1975)
Adv. Biochem. Psychopharmacol. 14, 131–151
39. Leppik, R. A., Mynett, A., Lazareno, S., and Birdsall, N. J. (2000) Mol. Phar-
macol. 57, 436–445
40. Graham, R. M., Perez, D. M., Hwa, J., and Piascik, M. T. (1996) Circ. Res. 78,
737–749
41. Shapiro, R. E., Winters, B., Hales, M., Barnett, T., Schwinn, D. A., Flavahan,
N., and Berkowitz, D. E. (2000) Hypertension 36, 553–5602 R. J. Lewis and P. F. Alewood, unpublished observations.
1-Adrenoreceptor Antagonism by 	-TIA 34457
 by on Septem
ber 4, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
